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1270clustering components, and their integration with
“omics” and with data from genetic and molecular
pathways, are important for the construction of
robust clinical phenotypes. Furthermore, to explain
the functional behavior of cardiac phenotypes,
we should recognize the clinical signiﬁcance of the
regulatory and compensatory role of the remod-
eling myocardial mechanism and of the func-
tional signiﬁcance of the homeostatic neurohumoral
systems.*George E. Louridas, MD, PhD
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Data of Previously Published Chronic
Heart Failure TrialsWe thank Dr. Madias for his interest in our editorial
(1). We appreciate his thoughtful remarks regarding
the importance of adopting a more liberalized clas-
siﬁcation system for heart failure with reduced
ejection fraction, both in clinical practice as well as
in research. We agree that additional cluster ana-
lyses are needed both from large clinical trials and
electronic health records for better phenotyping of
heart failure with reduced ejection fraction patients.
This is a logical ﬁrst step toward building a new
taxonomy for heart failure with reduced ejection
fraction, which will be pivotal in designing cost-
effective and successful clinical trials in the future.*Gary S. Francis, MD
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Systems Biology and Clinical Phenotypes of
Heart Failure SyndromeWe thank Dr. Madias for his insightful comments
regarding our recent publication in the Journal (1). We
wholeheartedly agree with the assertion that the com-
munity of clinicians and researchers should strive for a
more objective methodology by which to classify the
syndrome of heart failure. This is in agreement with the
recent call by the National Research Council report that
calls for a new taxonomy of disease based on both
clinical and molecular measures in order to provide a
more accurate classiﬁcation of disease, with the ulti-
mate goal of enhancing diagnosis and treatment (2).
Drs. Louridas and Lourida suggest that we should
integrate more pathophysiological information into
clustering algorithms. We agree that this approach
might allow for further reﬁnement in phenotyping of
heart failure and would suggest that future studies
include biomarkers representing diverse biological
pathways to encompass the complex biology of heart
failure to the greatest extent possible.
Dr. White articulated the need for an improved
classiﬁcation of heart failure almost a hundred years
ago (3), prompting the widespread use of measures
such as New York Heart Association class. Countless
therapeutic advances have been anchored in the para-
digm established by existing classiﬁcation schemes
(New York Heart Association class, left ventricular
ejection fraction). However, our understanding of
heart failure has dramatically outpaced these de-
scriptors of the syndrome; integrating biological and
clinical data using advanced analytics has the
